Teo Jin Yao, Kam Juinn Huar, Chan Chung Yip, Goh Brian K P, Wong Jen-San, Lee Victor T W, Cheow Peng Chung, Chow Pierce K H, Ooi London L P J, Chung Alexander Y F, Lee Ser Yee
1 Department of Hepatopancreatobiliary and Transplantation Surgery, Singapore General Hospital, Singapore ; 2 Duke-NUS Graduate Medical School, Singapore ; 3 Division of Surgical Oncology, National Cancer Center Singapore, Singapore ; 4 Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore.
Hepatobiliary Surg Nutr. 2015 Dec;4(6):379-90. doi: 10.3978/j.issn.2304-3881.2015.06.06.
Minimally invasive surgery has been one of the recent developments in liver surgery, laparoscopic liver resection (LLR) was initially performed for benign lesions at easily accessible locations. As the surgical techniques, technology and experience improved over the past decades, LLR surgery had evolved to tackle malignant lesions, major resections and even in difficult locations without compromising safety and principles of oncology. It was also shown to be beneficial in cirrhotic patients. We describe our initial experience with LLR in a population with significant proportion having cirrhosis, emphasising our approach for lesions in the posterosuperior (PS) segments of the liver (segments 1, 4a, 7, and 8).
A review of patients undergoing LLR in single institution from 2006 to 2015 was performed from a prospective surgical database. Clinicopathological, operative and perioperative parameters were analyzed to compare outcomes in patients who underwent LLR for PS vs. anterolateral lesions (AL).
LLR was performed in consecutive 197 patients, with a mean age of 60 years. The indications for resection were hepatocellular carcinoma (HCC) (n=105; 53%), colorectal cancer liver metastasis (n=31; 16%), other malignancies (n=19; 10%) and benign lesions (n=42; 21%). A significant proportion had liver cirrhosis (25.9%). More females underwent surgery in the AL group and indications for surgery were similar between both groups. Major liver resection was performed more frequently for the PS group than for the AL group (P<0.001) and significantly more PS resections was performed in our latter experience (P=0.02). The mean operative time and the conversion rate were significantly greater in the PS group than in the AL group (P≤0.001 and 0.03, respectively). However, the estimated blood loss (EBL), rate of blood transfusion and mean postoperative stay were similar in the two groups (P=0.04, 0.88 and 0.92, respectively). The overall 90-day morbidity and mortality rate was 21.3% and 0.5% respectively, with no differences between the two groups. Surrogates of difficulty such as operative time, blood loss, conversion and outcomes e.g., morbidity and mortality, were similar in patients who underwent PS resections with or without cirrhosis.
LLR in selected patients is technically feasible and safe including cirrhotic patients with lesions in the PS segments.
微创手术是肝脏外科领域近年来的进展之一,腹腔镜肝切除术(LLR)最初用于治疗位于易于接近部位的良性病变。在过去几十年中,随着手术技术、设备和经验的不断进步,LLR手术已发展到可用于治疗恶性病变、进行大范围切除,甚至是在困难部位进行手术,同时不影响安全性和肿瘤学原则。研究还表明,LLR对肝硬化患者有益。我们描述了我们在LLR方面的初步经验,该人群中很大一部分患有肝硬化,重点介绍了我们针对肝脏后上(PS)段(第1、4a、7和8段)病变的处理方法。
从一个前瞻性手术数据库中回顾了2006年至2015年在单一机构接受LLR的患者。分析临床病理、手术和围手术期参数,以比较接受PS段病变与前外侧(AL)病变LLR患者的结局。
连续197例患者接受了LLR,平均年龄60岁。切除指征为肝细胞癌(HCC)(n = 105;53%)、结直肠癌肝转移(n = 31;16%)、其他恶性肿瘤(n = 19;10%)和良性病变(n = 42;21%)。很大一部分患者患有肝硬化(25.9%)。AL组接受手术的女性更多,两组的手术指征相似。PS组比AL组更频繁地进行大范围肝切除(P < 0.001),并且在我们后期的经验中,PS段切除显著更多(P = 0.02)。PS组的平均手术时间和中转率显著高于AL组(分别为P≤0.001和0.03)。然而,两组的估计失血量(EBL)、输血率和平均术后住院时间相似(分别为P = 0.04、0.88和0.92)。总体90天发病率和死亡率分别为21.3%和0.5%,两组之间无差异。在接受PS段切除的患者中,无论有无肝硬化,诸如手术时间、失血量、中转情况等困难指标以及诸如发病率和死亡率等结局指标均相似。
对于选定患者,包括PS段有病变的肝硬化患者,LLR在技术上是可行且安全的。